Details for Patent: 6,355,656

Title:	Phenidate drug formulations having diminished abuse potential
Abstract:	Phenidate drug formulations are provided having reduced potential for drug abuse. Dosage forms for treating Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, AIDS Dementia Complex and cognitive decline in HIV-AIDS are provided which minimize drug hypersensitivity, toxicity, side effects, euphoric effect, and drug abuse potential. Such dosage forms comprise D-threo stereoisomer of a phenidate in the substantial absence of all other stereoisomers.
Inventor(s):	Zeitlin; Andrew L. (Millington, NJ), Dariani; Maghsoud M. (Fanwood, NJ)
Assignee:	Celgene Corporation (Warren, NJ)
Filing Date:	May 25, 1999
Application Number:	09/318,151
Claims:	1. A pharmaceutical unit dosage comprising from about 1 to about 50 milligrams of D-threo-methylphenidate or a pharmaceutically acceptable salt thereof said dosage having less than 10% by weight of other stereoisomers of methylphenidate or the salt thereof. 2. The unit dosage of claim 1 comprising from about 2 to about 20 milligrams of D-threo-methylphenidate. 3. The unit dosage of claim 1 comprising from about 21/2 to about 12 milligrams of D-threo-methylphenidate. 4. The unit dosage of claim 1 in a form suitable for oral administration.